Login to Your Account

Financings Roundup

Vivus' Post-Panel Stock Surge Prompts Hefty Public Offering

By Jennifer Boggs
Managing Editor

Thursday, March 1, 2012
Given the 125 percent stock surge after last week's positive FDA panel review for obesity candidate Qnexa (phentermine/topiramate), Vivus Inc.'s plan for a public offering comes as little surprise.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription